Leerink Partnrs Issues Optimistic Estimate for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Karyopharm Therapeutics in a research note issued on Wednesday, October 8th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($2.92) per share for the quarter, up from their previous forecast of ($3.26). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ Q4 2025 earnings at ($1.65) EPS, FY2025 earnings at ($10.50) EPS and FY2026 earnings at ($2.32) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The business had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.

KPTI has been the subject of several other research reports. Piper Sandler restated an “overweight” rating and issued a $12.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday. Robert W. Baird lowered their target price on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright cut shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 16th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $20.60.

Karyopharm Therapeutics Stock Down 5.5%

NASDAQ KPTI opened at $5.50 on Monday. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $16.95. The stock has a market capitalization of $47.69 million, a PE ratio of -0.38 and a beta of 0.34. The firm has a 50 day moving average of $6.00 and a two-hundred day moving average of $5.17.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of the company. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics during the 2nd quarter worth $45,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $56,000. Silverback Asset Management LLC increased its holdings in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).